Halozyme Therapeutics Inc logo

HALO - Halozyme Therapeutics Inc Share Price

$18.14 0.6  3.7%

Last Trade - 7:45pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.94bn
Enterprise Value £1.92bn
Revenue £157.3m
Position in Universe 1397th / 6323
Bullish
Bearish
Unlock HALO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HALO Revenue Unlock HALO Revenue

Net Income

HALO Net Income Unlock HALO Revenue

Normalised EPS

HALO Normalised EPS Unlock HALO Revenue

PE Ratio Range

HALO PE Ratio Range Unlock HALO Revenue

Dividend Yield Range

HALO Dividend Yield Range Unlock HALO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HALO EPS Forecasts Unlock HALO Revenue
Profile Summary

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated August 23, 2007
Public Since January 30, 2003
No. of Shareholders: 19,877
No. of Employees: 132
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 138,069,410
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HALO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HALO
Upcoming Events for HALO
Thursday 30th April, 2020
Halozyme Therapeutics Inc Annual Shareholders Meeting
Friday 1st May, 2020 Estimate
Halozyme Therapeutics Inc Annual Shareholders Meeting
Tuesday 5th May, 2020 Estimate
Q1 2020 Halozyme Therapeutics Inc Earnings Release
Tuesday 4th August, 2020 Estimate
Q2 2020 Halozyme Therapeutics Inc Earnings Release
Similar to HALO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.